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Abstract: Thioctic acid is a multipotent antioxidant compound existing as dextrorotatory (+),
eutomer and naturally occurring and levorotatory (−). It has been proven to help fight many
pathologies and is sold as racemate. In agreement with studies claiming a greater biopotency of the
eutomer compared to the levorotatory compound, we recently preclinically and clinically showed
that (+) thioctic acid is a pain-reliever as effective as double-dosed racemate. We investigated acute
and subchronical toxicity of (+/−) thioctic acid, (−) thioctic acid, (+) thioctic acid and (+) salt thioctic
acid on Sprague–Dawley rats. For acute toxicity, compounds were administered intraperitoneally
(i.p.) with a single-injection at 125, 240, 360, 480 µmol/kg, then rodents were tested for motorial
coordination and minimum lethal dose (LDmin). A subtoxic dose (360 µmol/kg) was administered i.p.
for 15 days and we finally evaluated motorial impairment, glycemia, organ toxicity, and apoptosis state.
Acutely administered, the highest doses of all thioctic acid compounds negatively affected motorial
ability and (−) thioctic acid LDmin resulted higher than the others. Subchronic administrations caused
overall body weight loss, motorial impairment, mass loss in some organs. (+/−) and (−) thioctic acid
injections enhanced caspase-3 activity in some organs, (−) enantiomer-treated animals displayed more
marked organ toxicity signs. Together with our previous study on the biologic role of enantiomers,
these data suggest a therapeutic use of (+) enantiomer-based formulations, thus lowering dose and
toxicity without affecting the positive effects brought by the drug.
Keywords: neuropathic pain; thioctic acid; antioxidant; food supplement; caspase-3
1. Introduction
Thioctic acid (chemical formula: C8H14O2S2) is a dithiol eight-carbon molecule [1] with a chiral
center which induces its isomerization into two optical enantiomers: (+) thioctic acid, the eutomer and
(−) thioctic acid. The production of both two isomers occurs during non-enantioselective chemical
(nonbiologic) synthesis (Figure 1) [2]. The eutomer is synthetized de novo in mammalian mitochondria
by the enzyme lipoic acid synthase (LASY), from octanoic acid and cysteine [3]. Only (+) thioctic
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acid is synthetized by the cells and is biologically active: it is part of a mitochondrial complex
which contributes to the synthesis and degradation of glycine. In addition—thanks to its amide
linkage to lysine residue—(+) thioctic acid acts as a cofactor for some critical mitochondrial enzymes:
pyruvate dehydrogenase (PDH), branched chain α-keto-acid dehydrogenase (KDH), α-ketoglutarate
dehydrogenase (KGDH) [4]. Thioctic acid has a strong antioxidant activity explicated through different
mechanisms exerted by the redox pair thioctic acid/dihydrothioctic acid: scavenging free radicals,
restoring endogenous antioxidant molecules (such as vitamins A, C, E and glutathione) and chelating
metal ions, thus reducing the production of reactive oxygen species [4,5]. Therefore, it has become
therapeutically attractive for fighting oxidative stress underlying many disease processes such as
polyneuropathies, diabetes complications, hepatopathies, and hypertension [6–9]. Since dietary sources
(liver, heart, kidney, broccoli, spinach, etc.) contain low quantities of thioctic acid resulting in scarce
bioavailability [5,10], this acid is sold as drug or dietary supplement in racemic form that increased its
bioavailability [4]. Many studies highlighted that the eutomer has more biopotency than (−) thioctic
acid [11–13] and, moreover, (+) enantiomer was proved to be longer available in the plasma than (−)
enantiomer [14]. Previous studies of our groups fitted perfectly in this context: in a model of peripheral
neuropathy induced by chronic constriction injury of sciatic nerve in hypertensive rats, we showed the
analgesic, antioxidant and neuroprotective efficacy of a chronic administration of alpha lipoic acid,
being (+) thioctic acid more active than (−) enantiomer and as active as double dose of racemate or
even more than it [12,15].
The present study attempted to outline an acute and subchronic toxicological profile of thioctic
acid enantiomers and racemic form. To assess acute toxicity profile, we evaluated motorial impairment
and defined a minimum lethal dose (LDmin); under a prolonged treatment (15 days) at a sublethal
dose, we investigated motorial impairment, hematic values and then ex vivo analysis ensued to
outline subchronic toxicity profile of the substances. In summary, our data reported the presence of
some toxic effects following acute and subchronic treatments with all compounds, but (+) enantiomer
displayed a slightly lower subchronic toxicological profile, with no differences between acid and salt
form, than (−) enantiomer and racemic form. The little toxicity and higher biologic activity of the
dextrorotary enantiomer suggest the therapeutic use of the eutomer alone, thus allowing reduction of
dosage and general toxicity.
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weighed approximately 200–250 g at the beginning of the experimental procedure. Rats were 
accommodated in a laboratory animal facility (CeSAL, Centro Stabulazione Animali da Laboratorio, 
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2. Materials and Methods
2.1. Animals
The present study was carried on male Sprague–Dawley rats (Envigo, Varese, Italy), which weighed
approximately 200–250 g at the beginning of the experimental procedure. Rats were accommodated in a
laboratory animal facility (CeSAL, Centro Stabulazione Animali da Laboratorio, University of Florence)
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and used one week after their arrival. Each cage (size 26 × 41 cm2) housed four rats, which were
given a standard laboratory diet and tap water ad libitum. Animals were kept at 23 ± 1 ◦C with a 12 h
light/dark cycle, starting light at 7 a.m. All animal manipulations were carried out according to the
directive 2010/63/EU of the European Parliament and of the European Union council (22 September
2010, amended by Regulation (EU) 2019/1010) on the protection of animals used for scientific purposes.
The ethical policy of the University of Florence complies with the guide for the care and use of laboratory
animals of the US National Institutes of Health (NIH Publication No. 85–23, revised 1996; University
of Florence assurance number: A5278-01). The below described experiments were approved by the
Italian Ministry of Health (No. 54/2014-B) and by the animal subjects review board of the University
of Florence. Since the study involved animals, the experiments were reported according to ARRIVE
guidelines [16]. All efforts were made to reduce at minimum extent animal suffering and the number
of animals used.
2.2. Animal Treatments
Thioctic acid, as racemate, acid and tromethamine salt (+) enantiomer, (−) enantiomer, was pursued
from Sintactica (Milan, Italy). Compounds were solubilized in NaOH-supplemented physiologic
solution and buffered to 7.4 pH by adding HCl. In acute toxicity tests, rats were divided in groups
(n = 6 per group) and treated with intraperitoneal (i.p.) injection of 125, 240, 360, 480 µmol/kg of each
compound (corresponding to 25, 50, 75 and 100 mg/kg of (+/−) thioctic acid) while controls group
(n = 6 per group) received the same amounts of vehicle. Acute toxicity tests were performed 30 min
and 2 h following injections. Subchronic toxicity tests were performed 24 h after the last injection of
15-day treatments with 360 µmol/kg of each thioctic acid isoform.
2.3. Rotarod Test
Motor coordination was measured by the rotarod test according to [17]. The apparatus (Ugo Basile,
Varese, Italy) consisted of a base platform and a rotating rod with a diameter of 3 cm and a non-slippery
surface. The rod was placed at a height of 15 cm from the base. The rod—30 cm in length—was divided
into 5 equal sections by 6 disks. Thus, up to five mice were tested simultaneously on the apparatus,
with a rod rotating speed of 10 revolutions per minute. The integrity of motor coordination was
assessed on the basis of the number of falls from the rod and the overall time of continuous walking in
10 min (cutoff time 600 s). A training pretest session was performed 24 h before acute treatment and at
the beginning of the subchronic treatment.
2.4. Collection of Blood and Glycemia Analysis
Blood was collected immediately after sacrifice into Eppendorf tubes containing heparin (20 µL,
25,000 IU/5 mL). Plasmatic fraction was separated by spinning at 2000× g for 15 min and glucose levels
were measured using Elite apparatus (Bayer, Leverkusen, Germany).
2.5. Tissue Explant
Following subchronic toxicity tests, rats were sacrificed by cervical dislocation and tissues explant
was performed: thymus, lung, liver, spleen, kidney, suprarenal glands, skeletal muscle digitorum longus
and spinal cord were collected. A portion of them was immediately frozen with liquid nitrogen for
enzymatic and immunoblotting experiments; the rest was fixed in situ with 10% formalin in phosphate
buffered saline (pH 7.4) and then bathed in sucrose gradients.
2.6. Caspase-3 Activity
A 20-mg portion of tissue was homogenized in lysis buffer containing Tris HCl 200 mM pH 7.5,
NaCl 2 M, EDTA 20 mM, Triton X-100 0.2% and centrifuged for 5 min at 5000× g. Fifty microliters of
the supernatants were incubated with 25-µM fluorogenic peptide caspases 3 substrate rhodamine 110
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bis-(N-CBZ-L-aspartyl-L-glutamyl-L-va-lyl-L-aspartic acid amide) (EnzChek® Caspase-3 Assay Kit,
Molecular Probes, Milano, Italy) at 25 ◦C for 30 min in a buffer solution composed by PIPES 10 mM pH
7.4, EDTA 10 mM, CHAPS 0.5%, modifying experimental protocol from [18]. The amount of cleaved
substrate per sample was measured in a 96-well plate fluorescent spectrometer (PerkinElmer, Milan,
Italy) setting the following wavelengths: excitation at 496 nm and emission at 520 nm.
2.7. Histological Analysis
The liver and kidney were removed, cut into small pieces and fixed in 10% neutral buffered formalin.
After dehydration in gradual ethanol (50% to 100%), they were cleared in xylene, paraffin-embedded
and cut in consecutive 5-µm-thick sections. Sections were stained with hematoxylin and eosin dye
and Azan–Mallory and observed under a light microscope (objective Zeiss Plan Apo 10, Oberkochen,
Germany) at an original magnification of 20× and 40×.
2.8. Statistical Analysis
Analysis were performed on 6 rats for each treatment. All assessments were made by researchers
blinded to animal treatments. Results were expressed as means ± SEM and the analysis of variance
was performed by one-way ANOVA. A Fisher’s significant difference procedure was used as post
hoc comparison. p-values less than 0.05 were considered significant. Data were analyzed using the
“Origin” software version 9 (OriginLab, Northampton, MA, USA).
3. Results
3.1. Acute Toxicity
The present study focused on acute and subchronic toxicity induced by thioctic acid isoforms.
At first, we studied acute toxicity: we evaluated ataxia by rotarod test as shown by the results in
Figure 2. The rodents were injected i.p. with 125-, 240-, 360-, 480-µmol/kg thioctic acid isoforms and
after 30 and 120 min we reported the falls from the rotating rod and the balance time on the rod.
Thirty minutes after the administration, independently from any dose and isoform used, thioctic acid
did not alter the number of falls recorded during control animals’ performances (not shown) which
resemble pretest results. On the contrary, all the isoforms at 360 and 480 µmol/kg induced a statistically
significant increase of falls from the rotating rod two hours after the injections: racemic form and
both (+) enantiomers (acid and tromethamine salt compounds) caused from five-fold to six-fold
rise, while the effect of (−) enantiomer was slightly minor. The comparison panel clearly showed no
significant changes in number of falls at the two highest doses (360 and 480 µmol/kg) among the
different groups of treatment. Time of balance on the rotating rod was expressed in seconds: 600 s were
arbitrarily chosen as time period useful to highlight motor impairments and were set as cutoff time.
This time was reached by all rodents during pretest performed the day before. The data concerning time
of balance revealed a similar toxicity pattern (“balancing time”): at 125 and 240 µmol/kg, all thioctic
acid isoform allowed the rodents to walk continuously on the rod for 600 s, like the pretest, while at 360
and 480 µmol/kg the racemic mixture and the (+) enantiomers reduced by 70% this time of walking;
the same reduction was observed when administering 480 µmol/kg of (−) enantiomer.
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Figure 2. Effects of acute toxicity treatments: ataxia (Rota Rod test). The graphs represent: the number 
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enantiomer, (−) enantiomer); a comparison among all groups of treatments at 360 and 480 µmol/kg 
two hours after the injection; the time of balanced walking after 2 h. Each value represents the mean 
± SEM of 6 rats per group. * p < 0.05 vs pretest. 
Another investigated parameter was the minimum lethal dose (LDmin): racemic mixture, acid 
and salt (+) enantiomers displayed lethality at 960 µmol/kg, while (−) isoform was scaled up till 1450 
µmol/kg, before being mortal (Table 1). 
Table 1. Minimum lethal dose of i.p. injected (+/−) thioctic acid, (+) and (−) enantiomers. 
Thioctic Acid Isoform Minimum Lethal Dose (LDmin) 
(+/−) thioctic acid 960 µmol/kg i.p. 
(+) tromethamine salt thioctic acid 960 µmol/kg i.p. 
(+) thioctic acid 960 µmol/kg i.p. 
(−) thioctic acid 1450 µmol/kg i.p. 
3.2. Subchronic Toxicity 
3.2.1. Body Weight and Hematic Parameters 
Considering these preliminary data, we moved on studying subchronic toxicity effects: for two 
weeks treatments were repeated administering every day i.p. all the substances at the minimum toxic 
dose 360 µmol/kg, which was outlined by previously performed acute toxicity experiments. The first 
effect to be evaluated was the variation of body weight, by measuring it every day, from Day 0 to 
Day 15 (Figure 3A). After six days of injections with all isoforms of thioctic acid, rodents lost weight 
in comparison to control animals treated with physiological solution, which gained weight. If 
treatments with (+) salt and acid enantiomers induced anorexic effects to the same extent, a noticeable 
major impact on body weight was exerted by (−) enantiomer administrations: a significant difference 
of outcomes was registered on Day 9 and 15 than racemic mixture and on Day 15 than (+) isoform 
injections. We then evaluated again motor coordination ability: the number of falls increased by about 
4-fold, independently from the isoform injected (Figure 3B), whereas the walking time period on the 
rotating rod was not affected by the substances (Figure 3C). Thioctic acid injections did not modify 
Figure 2. Effects of acute toxicity treatments: ataxia (Rota Rod test). The graphs represent: the number
of falls observed 30 and 120 min after treatments with increasing concentrations (125, 240, 360 and
480 µmol/kg) of thioctic acid (t.a.) isoforms (racemate, (+) tromethamine salt enantiomer, (+) acid
enantiomer, (−) enantiomer); a comparison among all groups of treatments at 360 and 480 µmol/kg two
hours after the injection; the time of balanced walking after 2 h. Each value represents the mean ± SEM
of 6 rats per group. * p < 0.05 vs. pretest.
Another investigated parameter was the minimum lethal dose (LDmin): racemic mixture, acid and
salt (+) enantiomers displayed lethality at 960µmol/kg, while (−) isoform was scaled up till 1450µmol/kg,
before being mortal (Table 1).
Table 1. Minimum lethal dose of i.p. injected (+/−) thioctic acid, (+) and (−) enantiomers.
Thioctic Acid Isoform Minimum Lethal Dose (LDmin)
(+/−) thioctic acid 960 µmol/kg i.p.
(+) tromethamine salt thioctic acid 960 µmol/kg i.p.
(+) thioctic acid 960 µmol/kg i.p.
(−) thio tic acid 145 l/kg i.p.
3.2. Subchronic Toxicity
3.2.1. Body Weight and Hematic Parameters
Considering these preliminary data, we moved on studying subchronic toxicity effects: for two
weeks treatme ts w r repeated administering e ry day i.p. all the substan es at the minimum toxic
dose 360 µ ol/kg, which w s outlined by previousl performed acute toxicity experi ents. The first
effect to be evaluated was the variation of body weight, by me s ring it every day, from Day 0 to
Day 15 (Figure 3A). After six days of injections with all isofor s of thioctic acid, rodents lost weight in
comparison to control animals treated with physiological solution, w ich gaine weight. If treatments
with (+) salt and acid enantio ers induced anorexic effects to the same extent, a noticeable major
impact on body weight was ex rted by (−) e antiomer administrations: a significa t difference of
outcomes was registered on D y 9 and 15 than r cemic mixture and on D y 15 than (+) isoform
injections. We then evaluated again motor coordination ability: the number of falls increased by about
4-fold, independently from the isoform injecte (Figure 3B), whereas th walking tim p riod on the
rotating rod was ot affected by the substances (Figure 3C). Thioctic acid injections did n t modify
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glycemia values since at the end of the treatments they measured around 80 mg/dL in all groups
(Appendix A, Figure A1).
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3.2.2. Ex vivo Analysis: Organ Mass 
By the end of the treatment the animals were sacrificed and ex vivo analysis was carried on. 
First, main organs were weighed: in all treated groups heart (Figure 4A) and spleen (Figure 4B) lost 
15% and 23% of mass than control, respectively; liver lost 7% of weight in almost all treated groups 
and this reduction rose up to 18% when administrating (−) enantiomer (Figure 4C); the mass of 
thymus was nearly halved only by injections of racemic and (−) enantiomeric thioctic acid, decreasing 
from 564 g to 376 g and 324 g, respectively (Figure 4D). We noticed that, when animals were treated 
with (+) enantiomers, suprarenal gland’s weight rose in a statistically significant way, increasing by 
around 1.5-fold from 36.7 to 50 g (Figure 4E), while all the treatments had no effects on lungs and 
kidneys (Figure 4F,G). A summary of organ mass variation is outlined in Appendix A, Table A1. 
Figure 3. Subchronic toxicity treatments: body weight and ataxia. Effects of 15-day subchronic
toxicity treatment with 360 µmol/kg of thioctic acid (t.a.) racemate, (+) enantiomer tromethamine salt,
(+) enantiomer acid, (−) enantiomer on (A) body weight, (B) number of falls during 10 min of walking
on the rotating rod and (C) time f continuous walking on the rotating rod. Each value represents
the mean ± SEM of 6 rats per group. ◦ p < 0.05 vs. animals treated with physiological solution from
Day 6, * p < 0.05 vs. animals treated with racemate, ˆ p < 0.05 vs. animals treated with (+) enantiomers,
# p < 0.05 vs. animals treated with physiological solution.
3.2.2. Ex vivo Analysis: Organ Mass
By the end of the treatment the animals were sacrificed and ex vivo analysis was carried on. First,
main organs were weighed: in all treated groups heart (Figure 4A) and spleen (Figure 4B) lost 15%
and 23% of mass than control, respectively; liver lost 7% of weight in almost all treated groups and
this reduction rose up to 18% when administrating (−) enantiomer (Figure 4C); the mass of thymus
was nearly halved only by injections of racemic and (−) enantiomeric thioctic acid, decreasing from
564 g to 376 g and 324 g, respectively (Figure 4D). We noticed that, when animals were treated with (+)
enantiomers, suprarenal gland’s weight rose in a statistically significant way, increasing by around
1.5-fold from 36.7 to 50 g (Figure 4E), while all the treatments had no effects on lungs and kidneys
(Figure 4F,G). A summary of organ mass variation is outlined in Appendix A, Table A1.
Antioxidants 2020, 9, 749 7 of 16
Antioxidants 2020, 9, x FOR PEER REVIEW 7 of 17 
 
Figure 4. Subchronic toxicity treatments: organ weight. Effect of 15-day subchronic toxicity treatment 
with 360-µmol/kg thioctic acid (t.a.) isoforms (racemate, (+) tromethamine salt enantiomer, (+) acid 
enantiomer, (−) enantiomer) on: (A) heart, (B) spleen, (C) liver, (D) thymus, (E) adrenal gland, (F) right 
lung and (G) kidney. Each value represents the mean ± SEM of 6 rats per group. * p < 0.05 vs control; 
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3.2.3. Ex Vivo Analysis: Apoptotic State
The apoptotic state was checked by the measurement of the catalytic activity of caspase-3, the key
protein of apoptosis phenomenon, in order to observe cellular suffering in the kidney, the spinal cord
(Figure 5A,B), the liver and the skeletal muscles (Appendix A, Figure A2) [19]. Enzymatic activity of
caspase-3 was measured via the amount of cleaved rhodamine 110 substrate. Caspase-3 activity was
doubled (Figure 5A) in kidney of animals treated with (−) enantiomer; it was 2 and 3.5-fold more than
control in the spinal cord of racemic and (−) enantiomer treated rodents, respectively (Figure 5B). In the
liver and in the skeletal tissue, treatments induced no alteration in enzymatic activity (Figure A2).
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Figure 5. Subchronic toxicity treatments: caspase-3 activity in kidney and spinal cord. Effects of 15-
day subchronic toxicity treatment with 360-µmol/kg thioctic acid (t.a.) isoforms ((+/−) racemate, (+) 
tromethamine salt enantiomer, (+) acid enantiomer, (−) enantiomer) on enzymatic activity of Caspase-
3 in (A) kidney and (B) spinal cord. The amount of cleaved substrate rhodamine 110 was measured
by setting as wavelengths: excitation at 496 nm and emission at 520 nm. Each value represents the 
mean ± SEM of 6 rats per group. * p < 0.05 vs controls treated with physiological solution. 
3.2.4. Ex vivo Analysis: Organ Toxicity 
Finally, kidney and liver were investigated from a histological point of view, by processing 5 
micrometers sections with hematoxylin–eosin staining and Azan–Mallory technique. In Figure 6A
the biopsy preparation of control renal cortex displayed, even at low magnification, normal renal
corpuscles, which were instead absent from renal medulla (image not shown). The images of kidney 
sections from rodents treated with thioctic acid compounds ((+/−) thioctic acid, (+) salt enantiomer, 
(+) acid enantiomer and (−) enantiomer) showed alterations: the renal interstitium was edematous 
(asterisks in Figure 6B–E) even if lacking in mononucleate cellular infiltrates such as macrophages
and lymphocytes. Glomeruli were normal, but Bowman’s spaces were more dilated (arrows in Figure 
6C–E). Because of substances’ toxicity, there was a pathologic increase of luminal diameter of renal 
tubules, which was evident in all treated group samples compared to control ones, but more 
remarkably in (−) isoform treated rats (arrowheads in Figure 6E).
Figure 5. r ic toxicity treatments: caspase-3 act vity in kidney and spinal cord. Effects of
15-day subchronic toxicity treatment with 360-µmol/kg thio tic acid (t.a.) is forms ((+/−) racemate,
(+) tromethamine salt enantiomer, (+) acid enantiom r, (−) enantiomer) on enzymatic activity of
Caspase-3 in (A) ki ney and (B) spinal cord. The amount of cleaved substrate rhodamine 110 was
measured by setting as wavelengths: excitation at 496 nm and emission at 520 nm. Each value represents
the mean ± SEM of 6 rats per group. * p < 0.05 vs. controls treated with physiological s lution.
3.2.4. Ex Vivo Analysis: Organ Toxicity
Finally, kidney and liver were investigated from a histological point of view, by processing
5 micrometers sections with hematoxylin–eosin staining and Azan–Mallory technique. In Figure 6A
the biopsy preparation of control renal cortex displayed, even at low magnification, normal renal
corpuscles, which were instead absent from renal medulla (image not shown). The images of kidney
sections from rodents treated with thioctic acid compounds ((+/−) thioctic acid, (+) salt enantiomer,
(+) acid enantiomer and (−) enantiomer) showed alterations: the renal interstitium was edematous
(asterisks in Figure 6B–E) even if lacking in mononucleate cellular infiltrates such as macrophages and
lymphocytes. Glomeruli were normal, but Bowman’s spaces were more dilated (arrows in Figure 6C–E).
Because of substances’ toxicity, there was a pathologic increase of luminal diameter of renal tubules,
which was evident in all treated group samples compared to control ones, but more remarkably in (−)
isoform treated rats (arrowheads in Figure 6E).
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Turning attention to the liver, the hepatic parenchyma was not macroscopically affected by
repeated treatments with thioctic acid, since we reported the presence of normal capsule made of dense
connective tissue (images not shown). Microscopically (Figure 7), no alteration was observed in the
hematic irroration, because portal spaces were visible and carried many vases with different diameters.
First signs of toxicity effects were observed on hepatic lobules, characterized by irregular undefinable
borders, probably due to an edematous state, but again with no cellular infiltrate (images not shown).
At increased magnification (20×), treated hepatocytes (Figure 7B–E) were slightly different from their
physiological shape (Figure 7A): they were not polyhedral, nor with round nuclei, but they were slightly
swollen and displayed a lower staining affinity than that of controls (inserts in Figure 7A,E). On the
other side, the scattered chromatin content, the peripheral nucleoli, the presence of binucleated cells
followed the physiological pattern. Uncolored spots in the cytoplasm were probably due to technical
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procedures, such as glycogen and lipid extraction, therefore they did not point to morpho-functional
alterations: as a proof, cytoplasm was strongly eosinophil because of the high number of mitochondria
and, in addition, numerous free and rough endoplasmic reticulum-associated ribosomes provoked a
fine basophil granularity in the background. Sinusoids appeared to be coated with thin endothelial
cells, bearing dense and flattened nuclei and scarcely colored cytoplasm. Treatments with every
isoform of thioctic acid caused sinusoids to lightly dilate (asterisks in Figure 7B,C,E), especially around
the portal spaces, more prominently when using (−) enantiomer (Figure 7E). From the histological
analysis of heart, lung, adrenal and suprarenal glands and thymus we did not observe any alteration
which could be linked to thioctic acid treatments, both with racemic and enantiomeric forms; we only
show sections of organs of (−) isoform treated animals in Appendix A, Figure A3.
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4. Discussion
Thioctic acid is an organosulfur compound existing as two optical enantiomers: (+) and (−) thioctic
acid. It has a strong antioxidant activity explicated by the redox couple thioctic acid/dihydrothioctic acid
through different mechanisms: scavenging free radicals, restoring endogenous antioxidant molecules
and chelating metal ions, thus reducing in turn the production of reactive oxygen species [4,5]. The (+)
oriented eutomer was reported to be more biologically active than (−) enantiomer by a plethora of
studies [11–13,20], also in agreement with our recent preclinical studies on the pain-alleviating effects
of thioctic acid which concluded that the eutomer was more effective than the (−) enantiomer and as
beneficial as the double-dose of racemic thioctic acid [12,15]. The present comparison study represents
a novel point of view in the already existing literature context of preclinical and clinical toxicology
of thioctic acid: we report signs of light toxicity induced from both racemate and enantiomers,
with no relevant differences between the dextrorotary and levorotatory enantiomers except for some
discrepancies in subchronic treatment. Following the currently accepted table of rodent to human
dose conversion, the maximum dose of 100 mg/kg, used in this study, is comparable to 600 mg in
humans [21,22], a commonly used clinical dosage [23].
Acute and subchronical neurotoxicity was evaluated through rotarod test, which assesses ataxia
and motorial impairment, two signs of neurological damage [24]. In our study, acute intraperitoneal
administrations of all forms of thioctic acid were toxic at 360 and 480 µmol/kg (corresponding to
75 mg/kg and 100 mg/kg of racemic form) because they similarly altered neurological and motorial
capabilities of the rodents in all groups of treatment; (+/−) and (+) thioctic acid decreased time of
walking at 360 and 480 µmol/kg, while (−) thioctic acid only at 480 µmol/kg. Interestingly, minimum
lethal dose was lower for the racemic form and the eutomer (960 µmol/kg) than the threshold of (−)
enantiomer (1450 µmol/kg), maybe because of minor biological efficacy of the latter. This result was not
in line with a study from Cremer and colleagues who reported that the acute oral LD50 was in excess
of 2000 mg/kg, the NOAEL in excess of 61.9 mg/kg per day and the LOAEL in excess of 121 mg/kg
per day [25]. Many other studies, conducted on other animal species, reported different thresholds:
an oral LD50 of 400–500 mg/kg was described for dogs by [6]; Hill and collaborators claimed a 10-fold
or more sensitivity of cats than of rats, humans and dogs [26]. The discordance of minimum LD may
be due to the route of administration: intraperitoneal injections are characterized by larger absorption
area and more rapid absorption than oral administration; on the other hand the compound is subjected
to hepatic first-pass elimination.
Subchronic treatments with sublethal dose (360 µmol/kg) lasted 15 days. We observed weight
loss in all groups of treatment than control, but injections with levorotatory compound had a major
anorexic effect over two days than racemate group and (+) salt group. This side effect may be result of
an anorexic ability of the compounds, reported also by Cremer and coworkers, in a 2-year toxicity
study on 181 mg/kg oral intake per day and in a 8-week study, led by Timmers and colleagues, on the
effects of 0.5% racemic thioctic acid added to the high-fat and low-fat diet of rats [27,28]. There was
no homogeneous trend in our absolute organ weight data: only the masses of heart and spleen were
equally reduced by all types of administration, while levorotatory injections induced more pronounced
consequences on liver and thymus masses. The racemic form lowered the weight of thymus as well;
therefore weight loss could be ascribed to levorotatory action alone. On the other hand, a weight
increase was noticed for adrenal glands of only (+) enantiomer groups. These weight alterations may
be a compensatory response to an insult caused by thioctic acid.
All molecules also partially influenced motor coordination in a negative way at long term
(two weeks treatment). Light disturbance of motorial ability was observed in a 4-week toxicity study
by Cremer and his collaborators as well, which reported staggered and stilted gait in several female
rats from 30 to 180 min after oral administration of 121 mg/kg racemic lipoic acid [25]. This low-level
neurotoxicity must be balanced with the proved neuroprotective activity of the compound [12,15],
attempting to understand the biologic activity of thioctic acid by all its different interactions. Hematic
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values assessment revealed no variation of glycemia at the end of the treatment, in agreement with the
therapeutic effect of thioctic acid in sustaining and rising cellular glucose uptake [20].
We investigated the apoptotic state in the most relevant organs, through assessment of caspase-3
activity. Caspase-3 physiologically exists as an inactive pro-enzyme which is activated when apoptotic
processes start, therefore its activation ensues and explains, a suffering state of the cell [19]. Our results
cannot actually tell about an happening apoptotic state in any of the organs investigated, but there
was a positive modulation of caspase-3 activity in kidney and in spinal cord from animals treated
with (−) enantiomer and racemic form: prolonged injections with those isomers of thioctic acid
activated caspase-3 pro-enzyme, creating a condition which could be read as more prone to trigger
a pro-apoptotic cascade than a physiological one can be and suggesting an alarming cellular state.
Being both administrations toxic, (−) enantiomer appeared to be the responsible for the results induced
by racemic mixture. In literature we found voices opposing to our results: some studies reported an
antiapoptotic activity of thioctic acid, when the dietary supplement was administered orally and at
lower concentration (50 mg/kg) [29,30].
Histological analysis of kidney and liver revealed few signs of toxicity due to thioctic acid
administrations, but levorotatory enantiomer produced more prominent effects than the other
compounds. In the kidney, all the treatments with thioctic acid induced an edematous state of the renal
interstitium with no infiltrating monocytes, which could be typical of acute inflammation response and
Bowman’s capsule dilatation; lumen diameter appeared enlarged in all groups, but more markedly in
levorotatory-treated group. Thioctic acid may disturb membrane homeostasis, leading to leakage and
liquid accumulation—therefore ensuing slight edema formation and structure enlargement. A similar
pattern emerged from the histological analysis of liver: the hepatic lobules had irregular borders and
were larger, probably because of an edematous state lacking cellular infiltrate, maybe attributable
to an acute inflammatory process; hepatocytes were swollen; sinusoids dilated, more remarkably
in proximity of hepatic portals. Notably, sinusoidal dilatation was more evident in the group of
animals treated with (−) enantiomer. All these data—gathered from histological analysis of kidney and
liver—suggest slightly toxic effects produced by all isoforms of thioctic acid, but one of the side effects
was more stressed when animals were treated for 15 days with (-) enantiomer. In the scientific literature,
nephrotoxicity and hepatotoxicity were not confirmed by some studies reporting that thioctic acid
fought and reduced renal and liver damage induced by other insults, probably because our subchronic
dosage was higher (75 mg/kg vs. 50 and 25 mg/kg) and the route of administration was different
(intraperitoneal vs. oral) [29–31].
5. Conclusions
The natural antioxidant compound thioctic acid—usually sold as racemic mixture—is considered
health-improving in many pathologic states. Even if some clinical literature about the racemic
formulation did not report side effects [9,32–34], other preclinical studies have revealed some signs
of toxicity [25,27,28]. Our study highlighted little acute and subchronic toxicities of the compound
in all forms, which, in our opinion, could be markedly reduced, exploiting the high-efficacy of the
dextrorotatory eutomer: it could be administered alone and, as a consequence, the dose and the toxicity
would be lowered.
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Figure A2. Subchronic toxicity treatments: caspase-3 activity in liver and skeletal muscle. Effects of 
15-day subchronic toxicity treatments with 360 µmol/kg (+/−) t.a., (+) salt t.a., (+) t.a., (−) t.a. on 
enzymatic activity of Caspase-3 in liver (A) and skeletal muscle (B). The amount of cleaved rhodamine
110 substrate was measured by excitation at 496 nm and emission at 520 nm. Each value represents 
the mean ± SEM of 6 rats per group.
Figure A2. Subchronic toxicity treatments: caspase-3 activity in liver and skeletal muscle. Effects of
15-day subchronic toxicity treatments with 360 µmol/kg (+/−) t.a., (+) salt t.a., (+) t.a., (−) t.a. on
enzymatic activity of Caspase-3 in liver (A) and skeletal muscle (B). The amount of cleaved rhodamine
110 substrat was measured by excitation at 496 nm and emission at 520 nm. Each value represents the
mean ± SEM of 6 rats per group.
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Figure A3. Subchronic toxicity by (-) oriented enantiomer treatment: organ histology. Effects of 15-
day subchronic toxicity treatments with 360 µmol/kg (−) thioctic acid on histological features of heart 
(A), lung (B), adrenal gland (C), thymus (D). Staining with hematoxylin–eosin techniques; 20× 
magnification. 
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